BAIYUNSHAN PH (00874): Subsidiary Baiyunshan Hanfang Receives Marketing Authorization for Structured Triglycerides Chemical Raw Material

Stock News

Aug 29

BAIYUNSHAN PH (00874) announced that its subsidiary Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. ("Baiyunshan Hanfang") has recently received the Marketing Authorization Approval Notice for Structured Triglycerides Chemical Raw Material issued by the National Medical Products Administration.

According to the company, structured triglycerides serve as a key raw material for preparations including Structured Fat Emulsion Injection (C6-24) and Structured Fat Emulsion (20%)/Amino Acid (16)/Glucose (13%) Injection. These products are indicated for parenteral nutrition fat supplementation in patients who are unable to receive, have insufficient, or are contraindicated for oral or enteral nutrition intake.

The receipt of the Marketing Authorization Approval Notice for Structured Triglycerides by Baiyunshan Hanfang indicates that this raw material drug meets the relevant national pharmaceutical evaluation technical standards and can be produced and marketed. This approval will help enrich Baiyunshan Hanfang's pharmaceutical lipid raw material and excipient product portfolio, further enhancing the company's market competitiveness in lipid raw material and excipient products.

The company noted that receiving this Marketing Authorization Approval Notice will not have a significant impact on current period performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1194962127"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194962127\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194962127?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194962127","market":"fut","top_or_hot":-1,"title":"BAIYUNSHAN PH (00874): Subsidiary Baiyunshan Hanfang Receives Marketing Authorization for Structured Triglycerides Chemical Raw Material","media":"Stock News","content":"<p>BAIYUNSHAN PH (00874) announced that its subsidiary Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. (\"Baiyunshan Hanfang\") has recently received the Marketing Authorization Approval Notice for Structured Triglycerides Chemical Raw Material issued by the National Medical Products Administration.</p>\n<p>According to the company, structured triglycerides serve as a key raw material for preparations including Structured Fat Emulsion Injection (C6-24) and Structured Fat Emulsion (20%)/Amino Acid (16)/Glucose (13%) Injection. These products are indicated for parenteral nutrition fat supplementation in patients who are unable to receive, have insufficient, or are contraindicated for oral or enteral nutrition intake.</p>\n<p>The receipt of the Marketing Authorization Approval Notice for Structured Triglycerides by Baiyunshan Hanfang indicates that this raw material drug meets the relevant national pharmaceutical evaluation technical standards and can be produced and marketed. This approval will help enrich Baiyunshan Hanfang's pharmaceutical lipid raw material and excipient product portfolio, further enhancing the company's market competitiveness in lipid raw material and excipient products.</p>\n<p>The company noted that receiving this Marketing Authorization Approval Notice will not have a significant impact on current period performance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAIYUNSHAN PH (00874): Subsidiary Baiyunshan Hanfang Receives Marketing Authorization for Structured Triglycerides Chemical Raw Material</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAIYUNSHAN PH (00874): Subsidiary Baiyunshan Hanfang Receives Marketing Authorization for Structured Triglycerides Chemical Raw Material\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-29 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAIYUNSHAN PH (00874) announced that its subsidiary Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. (\"Baiyunshan Hanfang\") has recently received the Marketing Authorization Approval Notice for Structured Triglycerides Chemical Raw Material issued by the National Medical Products Administration.</p>\n<p>According to the company, structured triglycerides serve as a key raw material for preparations including Structured Fat Emulsion Injection (C6-24) and Structured Fat Emulsion (20%)/Amino Acid (16)/Glucose (13%) Injection. These products are indicated for parenteral nutrition fat supplementation in patients who are unable to receive, have insufficient, or are contraindicated for oral or enteral nutrition intake.</p>\n<p>The receipt of the Marketing Authorization Approval Notice for Structured Triglycerides by Baiyunshan Hanfang indicates that this raw material drug meets the relevant national pharmaceutical evaluation technical standards and can be produced and marketed. This approval will help enrich Baiyunshan Hanfang's pharmaceutical lipid raw material and excipient product portfolio, further enhancing the company's market competitiveness in lipid raw material and excipient products.</p>\n<p>The company noted that receiving this Marketing Authorization Approval Notice will not have a significant impact on current period performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1194962127","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194962127","pubTimestamp":1756459257,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAIYUNSHAN PH (00874) announced that its subsidiary Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. (\"Baiyunshan Hanfang\") has recently received the Marketing Authorization Approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"白云山酸化(00874)：子公司白云山汉方获结构化甘油三酯化学原料药上市许可","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":1,"00874":1},"content_text":"BAIYUNSHAN PH (00874) announced that its subsidiary Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. (\"Baiyunshan Hanfang\") has recently received the Marketing Authorization Approval Notice for Structured Triglycerides Chemical Raw Material issued by the National Medical Products Administration.\nAccording to the company, structured triglycerides serve as a key raw material for preparations including Structured Fat Emulsion Injection (C6-24) and Structured Fat Emulsion (20%)/Amino Acid (16)/Glucose (13%) Injection. These products are indicated for parenteral nutrition fat supplementation in patients who are unable to receive, have insufficient, or are contraindicated for oral or enteral nutrition intake.\nThe receipt of the Marketing Authorization Approval Notice for Structured Triglycerides by Baiyunshan Hanfang indicates that this raw material drug meets the relevant national pharmaceutical evaluation technical standards and can be produced and marketed. This approval will help enrich Baiyunshan Hanfang's pharmaceutical lipid raw material and excipient product portfolio, further enhancing the company's market competitiveness in lipid raw material and excipient products.\nThe company noted that receiving this Marketing Authorization Approval Notice will not have a significant impact on current period performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}